Search Results - "Pisini, M."

P739 RISK FACTORS AND TREATMENT OUTCOMES IN GENOTYPE 1 AND GENOTYPE 4 HEPATITIS C INFECTED PATIENTS FROM A REAL WORLD DATA ANALYSIS IN EUROPE by Moreno, C, Horsmans, Y, Flisiak, R, Van Vlierberghe, H, Trepo, E, Starkel, P, Jaroszewicz, J, Geerts, A, Pisini, M, Lantican, L, Koletzki, D

Get full text

PCR182 Patient Preferences for Tumor-Agnostic Therapies: Qualitative Insights and Challenges by Metekohy, C., Pisini, M., Janssen, E., Fernandez, G., Michaels-Igbokwe, C.

Get full text

HTA101 Diagnostic Testing (DTx) Costs: A Hidden Barrier to Accessing Histology-Independent Technologies (HITs) by Palmer, S, Walker, A, Gomez Montero, M, Guerra Primo, L, Wigfield, P, Rizzo, M, Pisini, M, Todd, E, Baculea, S

Get full text

PCN247 PROGRESSION-FREE SURVIVAL (PFS) WITH DARATUMUMAB- BORTEZOMIB-MELPHALAN-PREDNISONE (D-VMP) COMBINATION THERAPY AND ALTERNATIVE TREATMENTS FOR PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA (MM) INELIGIBLE FOR STEM CELL TRANSPLANTATION (ASCT): A PARAMETRIC NETWORK META-ANALYSIS (PNMA) by van Beekhuizen, S., Pisini, M., Gros Otero, B., Gaudig, M., Heeg, B.

Get full text

PCN245 APPLICABILITY OF A RESPONSE-BASED MODEL IN NEWLY-DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA by Hu, Y., van Beekhuizen, S., Pisini, M., Gros Otero, B., Tambour, M., Dansk, V., Heeg, B.

Get full text

PSY46 - A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY – THE CASE OF NOVEL TREATMENT COMBINATIONS FOR FRONTLINE TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM) by Le, H., Pan, F., Kowalski, B., Gaudig, M., Lam, A., Slavcev, M., Pisini, M.

Get full text

P250 Treatment patterns in treatment naïve high-risk non-muscle invasive bladder cancer across EU4 + UK: A real-world study by Simone, G., Darbas, S., Pisini, M., Mulhern Haughey, S., Molloy, N., Manuel, L., Skilling, J., Biondi, E., Brown, E., Rijken-Knol, A.

Get full text

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013 by Remes, Kari, Anttila, Pekka, Silvennoinen, Raija, Putkonen, Mervi, Ollikainen, Hanna, Terävä, Venla, Sinisalo, Marjatta, Kananen, Kristiina, Schain, Frida, Castren-Kortegangas, Päivi, Järvinen, Tiina M, Pisini, Marta, Wahl, Felix, Dixon, Tricia, Leval, Amy

“…Outcomes for patients with multiple myeloma (MM) have improved with the advent of novel therapies, however, real-world evidence of outcomes in clinical…”
Get full text

Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape by Borgsten, Fredrik, Gatopoulou, Xenia, Pisini, Marta, Tambour, Magnus, Schain, Frida, Jones, Christina V., Kwok, Kelvin Ho Man, Batyrbekova, Nurgul, Björkholm, Magnus

“…Objectives The introduction of novel drugs has significantly improved outcomes for multiple myeloma (MM) patients. This study describes survival, healthcare…”
Get full text

PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS by San-Miguel, J., Facon, T., Dimopoulos, M.A., Mateos, M., Cavo, M., Heeg, B., van Beekhuizen, S., Pisini, M., Nair, S., Lam, A., Slavcev, M.

Get full text

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide by Dimopoulos, Meletios A, Cavo, Michele, Mateos, Maria-Victoria, Facon, Thierry, Heeg, Bart, van Beekhuizen, Sophie, Nair, Sandhya, Pisini, Marta, Lam, Annette, Slavcev, Mary

“…▪ Introduction: Daratumumab-bortezomib-melphalan-prednisone (D-VMP) is a novel treatment regimen for newly diagnosed multiple myeloma patients who are…”
Get full text

PIN76 - Testing for Ns5a Resistance in Order to Optimize Antiviral Therapy With Simeprevir And Sofosbuvir 12 Weeks Appears Cost-Effective in Non-Cirrhotic Genotype 1 Hepatitis C Virus Treatment Experienced Patients by Westerhout, KY, Bouwmeester, W, Duchesne, I, Sbarigia, U, Pisini, M, Treur, M

Get full text

PIN96 - Real-World Hepatitis C Treatment Strategies in Denmark by Jalbert, J, Pisini, M, van Sanden, S, Nalpas, C, Bakshi, S, Duchesne, I, Amzal, B

Get full text

Real-World Hepatitis C Treatment Strategies in Denmark by Jalbert, J, Pisini, M, van Sanden, S, Nalpas, C, Bakshi, S, Duchesne, I, Amzal, B

Get full text

Testing for Ns5a Resistance in Order to Optimize Antiviral Therapy With Simeprevir And Sofosbuvir 12 Weeks Appears Cost-Effective in Non-Cirrhotic Genotype 1 Hepatitis C Virus Treatment Experienced Patients by Westerhout, KY, Bouwmeester, W, Duchesne, I, Sbarigia, U, Pisini, M, Treur, M

Get full text

PS1395 COMPARATIVE EFFECTIVENESS OF FRONT‐LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE by Facon, T., San‐Miguel, J., Usmani, S., Dimopoulos, M.A., Kumar, S., Mateos, M.‐V., Cavo, M., Heeg, B., Beekhuizen, S., Pisini, M., Nair, S., Lam, A., Slavcev, M., He, J.

“…Background: Several treatment options are available for patients with newly‐diagnosed multiple myeloma (NDMM) who are transplant ineligible. Most recently, the…”
Get full text

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service by Westerhout, Kirsten Y, Bouwmeester, Walter, Duchesne, Inge, Pisini, Marta, Piena, Marjanne A, Damele, Francesco, Gueron, Beatrice, Treur, Maarten, Belsey, Jonathan

“…Patients with genotype-1 hepatitis C virus infection who have failed to respond to standard therapy or who relapse following treatment may be considered for an…”
Get full text